Interventional Cardiology Devices Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons, Percutaneous Transluminal Coronary, Angioplasty (PTCA) Guide Wires, Stents, Catheters, Inferior Vena Cava (IVC) Filters, Intravascular Ultrasound Systems, Left Atrial Appendage (LAA) Devices and Others), By Disease Type (Congestive Heart Disease, Percutaneous Valve Replacement, Percutaneous Valve Repair, Coronary Thrombectomy, Others), By End User (Hospitals, Clinics, Cardiac Catheterization Labs, Ambulatory Surgical Centres) and Region

Interventional cardiology devices market size was valued at US$ 14.9 billion in 2023 and is projected to reach a value of US$ 24.6 billion by 2030, at a CAGR of 8.9 from 2024-2030. Interventional cardiology deals with the treatment of various heart diseases by using intravascular catheter-based techniques. Interventional cardiology devices are commonly used in the treatment of coronary artery disease, conventional artery disease, and aneurysm. In this technique, catheter is inserted into any large peripheral artery or vein with the help of fluoroscopy by catheter whole procedure.

Interventional cardiology provides controlled bleeding and fast recovery within a short period of time and reduce the complications for patients. The most commonly used interventional cardiology devices include balloon-inflation devices, coronary stents, and cutting balloon catheters among others. Increase in the incidence rate of various cardiovascular diseases, a rise in preference for minimally invasive procedures, growing clinical trials for the novel interventional cardiology devices, and technological advancements of devices are anticipated to fuel the interventional cardiology market over the forecast period. Moreover, favourable reimbursement policies for the devices, lifestyle changes, and rise in product launchings might bolster the market. However, stringent regulatory policies, product recall, high cost for the manufacturing of interventional cardiology devices & treatments, and lack of skilled professionals are expected to dampen the market over the forecast period.

Furthermore, the increasing incidence of cardiovascular disease along with the growing healthcare expenditure in medical devices is expected to push the market growth in the forecasted years. In addition, the rise in tobacco consumption and the growing incidence of obesity is also expected to fuel the growth. Several government and non-government organizations including educational institutes and key market payers, have conducted public awareness campaigns to raise awareness regarding cardiac disease and its treatments. The advancement of technology and procedures in healthcare facilities like innovative cardiovascular devices and regulatory approvals are expected to fuel the growth of the market in the forecasted years. However, the huge cost of interventional cardiac devices and the availability of alternative cardiac disease treatments are expected to hinder the growth of the market in the forecasted years. 

Key Developments

• In July 2021, Abbott launched its product XIENCE family of stents, which got USFDA’s approval for one month DAPT labeling for patients with high bleeding risk in US.